How many drugs treat Adrenogenital disorder?

Drug Landscape tracks 10 marketed treatments for Adrenogenital disorder (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/adrenogenital-disorder.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Adrenogenital disorder — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Adrenogenital disorder (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Adrenogenital disorder, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Decadron	dexamethasone	Generic (originally Merck)	Corticosteroid [EPC]	Annexin A1, Interleukin-4, Androgen receptor	1958-10-30
Medrol	methylprednisolone	Generic (originally Upjohn/Pfizer)	Glucocorticoid (corticosteroid)	Annexin A1, Short transient receptor potential channel 5, Glucocorticoid receptor	1957-10-01
Prelone	prednisolone	Generic (originally Schering)	Glucocorticoid (corticosteroid)	Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1	1955-01-01
Deltasone	prednisone	Generic (originally Schering)	Corticosteroid [EPC]	Annexin A1, Sodium/nucleoside cotransporter 1, Glucocorticoid receptor	1955-01-01
Solu-Cortef	hydrocortisone succinate	Pfizer	Corticosteroid	Glucocorticoid receptor	1955-01-01
Florinef	fludrocortisone	Generic	Mineralocorticoid	Annexin A1, Glucocorticoid receptor, Mineralocorticoid receptor	1954-01-01
Cortef	hydrocortisone	Generic (originally Merck/Upjohn)	Corticosteroid [EPC]	Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible	1952-01-01
Cortifoam	HYDROCORTISONE ACETATE	Pfizer	Corticosteroid	Corticosteroid-binding globulin	1951-01-01
prednison	prednison	Wen Zhang		Annexin A1, Sodium/nucleoside cotransporter 1, Glucocorticoid receptor
Cortisol	Cortisol	University of Zurich		Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 5 drugs in Adrenogenital disorder
Pfizer · 2 drugs in Adrenogenital disorder
Generic (originally Schering) · 2 drugs in Adrenogenital disorder
Generic (originally Merck/Upjohn) · 1 drug in Adrenogenital disorder
Generic (originally Upjohn/Pfizer) · 1 drug in Adrenogenital disorder
Hannover Medical School · 1 drug in Adrenogenital disorder
Leiden University Medical Center · 1 drug in Adrenogenital disorder
University of Zurich · 1 drug in Adrenogenital disorder
Wen Zhang · 1 drug in Adrenogenital disorder
Generic · 1 drug in Adrenogenital disorder
Generic (originally Merck) · 1 drug in Adrenogenital disorder

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Adrenogenital disorder:

Cite this brief

Drug Landscape (2026). Adrenogenital disorder — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/adrenogenital-disorder. Accessed 2026-06-10.

Adrenogenital disorder full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing